{"id":"W4296531529","doi":"10.1016/s2152-2650(22)01009-6","title":"Poster: ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cereblon; Ubiquitin ligase; Refractory (planetary science); Medicine; Lymphoma; Cancer research; Oncology; Internal medicine; Chemistry; Materials science; Ubiquitin; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655166,0.0007783263,0.0007771216,0.0001879147,0.0002438098,0.0005847783,0.0004696292,0.0008833442,0.01330808],"category_scores_gemma":[0.0003996676,0.0002153217,0.0006537697,0.0001521821,0.0002760792,0.0003696222,0.0001711022,0.001591948,0.002181342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005813509,"about_ca_system_score_gemma":0.0006217592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008039281,"about_ca_topic_score_gemma":0.001945167,"domain_scores_codex":[0.999851,0.00005066011,0.00001008913,0.00002763789,0.00002351853,0.00003706642],"domain_scores_gemma":[0.9998133,0.00003520948,0.0000373125,0.00001133148,0.00001738664,0.00008556545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.367958,0.01580979,0.005521022,0.002499749,0.001988834,0.0008010105,0.0002105485,0.003500327,0.1561955,0.0008960008,0.07700235,0.3676169],"study_design_scores_gemma":[0.4345742,0.3237337,0.06593639,0.0003070133,0.002774175,0.002508221,0.000179787,0.004961798,0.06342922,0.000990228,0.1004799,0.0001254437],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9469681,0.01602059,0.001487593,0.004002749,0.001080284,0.001684776,0.007930238,0.0006817951,0.02014383],"genre_scores_gemma":[0.9562675,0.006170968,0.001384837,0.002378705,0.0005650762,0.0005692351,0.007803346,0.0001039608,0.02475636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01330808,"threshold_uncertainty_score":0.04451996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04134696371287629,"score_gpt":0.3330528634368565,"score_spread":0.2917058997239802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}